May 28, 2004 by Charly TraversDon't Be a Biotech GamblerStand on solid ground by learning to assess the value of future drug programs.
May 26, 2004 by Charly TraversElan and Biogen File for ApprovalThere's a new multiple sclerosis drug on the horizon.
May 21, 2004 by Charly TraversProtein Design Labs' Mixed ResultsNuvion looks like a winner, while other drugs stumble.
May 12, 2004 by Charly TraversCubist Addresses a Niche MarketThis small firm is developing antibiotics to meet a medical need.
May 5, 2004 by Charly TraversGrowing Profits at ConneticsA broad product line is leading to sustainable growth.
Apr 30, 2004 by Charly TraversSales Weakness From InterMuneActimmune is stumbling without data to support its use.
Apr 29, 2004 by Charly TraversMedImmune's Big GambleFluMist may not be worth the gigantic R&D investment.
Apr 23, 2004 by Charly TraversA Difficult Drug LaunchWhile other biotechs have soared, Trimeris has paid for too-high expectations for its HIV drug therapy.
Apr 20, 2004 by Charly TraversGreat Googly Moogly, ImCloneThe biopharmaceutical company's stock is going crazy again.
Apr 19, 2004 by Charly Travers4 Promising Biotech IPOsSeveral recently gone-public biotechs boast surprisingly interesting drug pipelines.
Apr 16, 2004 by Charly TraversGenzyme's Minor DisappointmentThe latest sales figures show that a potential growth-driving drug may be stalling out.
Apr 12, 2004 by Charly TraversBargain Hunting in Big BiotechMedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors.
Apr 8, 2004 by Charly TraversIndevus' Big Score (Maybe)A small biotech company lands a potentially rich deal.
Apr 5, 2004 by Charly TraversA Biotech's Transition to DrugsA deal with Roche gives ArQule's drug program a leg up.
Apr 1, 2004 by Charly TraversAtrix Batting 1.000Atrix Laboratories' drugs have breezed past the Food and Drug Administration.
Mar 30, 2004 by Charly TraversGenentech: Priced for PerfectionCan Genentech's earnings growth keep up with its valuation?
Mar 26, 2004 by Charly TraversHuman Genome Getting on TrackWhat a novel concept for a drug company to focus on commercializing drugs.
